{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-003765","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.708988+00:00","generated_at":"2026-05-26T21:53:27.715519+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss","bullets":["Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).","Operating income $0.2M vs operating loss $0.5M in prior year quarter; six-month op income $0.7M.","Net income $0.1M ($0.00 EPS) vs net loss $0.4M ($(0.01) EPS) in prior year quarter.","Two largest contract manufacturing customers represented ~82% of total revenue in the six-month period.","Co-CEOs cite customer base expansion and core business focus as drivers of revenue growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-003765","json":"https://secwatch.observer/filing/0001437749-25-003765.json","markdown":"https://secwatch.observer/filing/0001437749-25-003765.md","text":"https://secwatch.observer/filing/0001437749-25-003765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774925003765/0001437749-25-003765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774925003765/inbp20250211_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:53:27.715519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}